title: Restoring hemostasis: fibrinogen concentrate versus cryoprecipitate.
abstract: Fibrinogen plays a key role in the coagulation process, and therefore maintaining adequate quantities of fibrinogen is an essential step in achieving satisfactory hemostasis in patients with acquired hypofibrinogenemia. Potential options for treating acquired hypofibrinogenemia in patients with uncontrolled bleeding include the use of cryoprecipitate or fibrinogen replacement therapy. This review provides a brief overview of the hemostatic process and the methods for assessing coagulopathy and discusses the efficacy and safety of cryoprecipitate and fibrinogen concentrate in restoring fibrinogen levels, achieving hemostasis and reducing transfusion requirements in different patient populations requiring rapid hemostasis. Other issues relevant to the clinical use of these agents in restoring hemostasis, including variations in product composition, preparation time and cost, are also examined.
authors.affiliation: Division of Hematology/Oncology, Mount Sinai Medical Center, One Gustave L Levy Place, Box 1079, NY 10029, USA. brianemd@gmail.com
authors.forename: Brian M
authors.initials: BM
authors.lastname: Elliott
authors.forename: Louis M
authors.initials: LM
authors.lastname: Aledort
mesh_terms: D000347:Afibrinogenemia / Q000097:blood / Q000276:immunology / Q000628:therapy*; D004266:DNA Virus Infections / Q000517:prevention & control; D005169:Factor VIII / Q000276:immunology / Q000627:therapeutic use*; D005340:Fibrinogen / Q000276:immunology / Q000627:therapeutic use*; D006487:Hemostasis; D006801:Humans; D012327:RNA Virus Infections / Q000517:prevention & control
chemical_list: C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen